| Musculoskeletal Diseases |
ACTRN12607000640404: Prospective trial of selective ultrasound-guided obturator nerve blockade for total knee replacement. |
|
|
| Not yet recruiting | 3 | 40 | | | Timothy Lee, Department of Anaesthesia | Patients undergoing unilateral total knee replacement. | | | | |
| Not yet recruiting | 3 | 114 | | | Westmead Hospital Research and Education Network, Western Sydney Local Health District Research and Education Network, Theramex Australia Pty Ltd., | End Stage Kidney Disease, fracture risk | | | | |
| Not yet recruiting | 3 | 122 | | | Townsville Hospital, Townsville Hospital | Hip Fracture Pain Management, Cognitive Impairment | | | | |
2020-002372-13: Study to evaluate the Safety and Efficacy of SRP-90001 in non ambulatory and ambulatory Subjects with Duchenne Muscular Dystrophy Etude destinée à évaluer la sécurité d’emploi et l’efficacité du SRP9001 chez des patients non ambulatoires et ambulatoires atteints de dystrophie musculaire de Duchenne |
|
|
| Not yet recruiting | 3 | 148 | Europe | Corticosteroide, NA, SRP-9001, Solution for infusion | Sarepta Therapeutics, Inc., SAREPTA THERAPEUTICS, INC., Sarepta Therapeutics, Inc. | Duchenne Muscular Dystrophy Dystrophie musculaire de Duchenne, Duchenne Muscular Dystrophy Dystrophie musculaire de Duchenne, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
ACTRN12619000555156p: Ketamine versus nitrous oxide plus intranasal fentanyl for paediatric fracture reduction in the emergency department: a prospective randomised comparison trial |
|
|
| Not yet recruiting | 3 | 216 | | | David Bishop, Redcliffe Hospital, in kind support | Paediatric fractures requiring manipulation / reduction
| | | | |
ACTRN12619000555156: Ketamine versus nitrous oxide plus intranasal fentanyl for paediatric fracture reduction in the emergency department: a prospective randomised comparison trial |
|
|
| Not yet recruiting | 3 | 216 | | | David Bishop, Redcliffe Hospital, in kind support | Paediatric fractures requiring manipulation / reduction
| | | | |
| Not yet recruiting | 3 | 332 | | | Dr William O'Callaghan, Queensland Orthopaedic Research Fund (QORF) | ankle fracture
; surgical site infection | | | | |
| Not yet recruiting | 3 | 332 | | | Dr William O'Callaghan, Queensland Orthopaedic Research Fund (QORF) | ankle fracture
, surgical site infection | | | | |
| Ongoing | 3 | 200 | Europe | Solution for injection, Tablet, Kineret, Colchicine, Naproxen 500 mg Teva, Prednisolon Teva 30 mg, Prednisolon Teva 5 mg | prof. dr. M.A.F.J. van de Laar, ZonMW, Sobi | scapho-lunate ligament injury | | | | |
ACTRN12616000521426: The EXPRESS pilot study: EXercise and PRotein Supplementation Supporting Autonomy in Prefrail & Frail Community Residing adults aged 65 years or older |
|
|
| Recruiting | 3 | 120 | | | University of Adelaide, Northern Communities Health Alliance Fund, University of Adelaide, Food and Nutrition, Commonwealth Science and Industrial Research Organisation, Centre for Physical Activity in Ageing, ACH , BMP Health Management Consultants | Frailty, mild cognitive impairment, musculoskeletal | | | | |
ACTRN12620001059954: Efficacy of perioperative Tranexamic Acid in patients undergoing trochanteric hip fracture surgery: A Randomized Placebo Controlled Trial.
|
|
|
| Recruiting | 3 | 184 | | | Dr.Faaiz Ali Shah, Dr.Faaiz Ali Shah | blood loss, hip fracture surgery | | | | |
ACTRN12621001587897: Assessing the effect of instilling gentamicin into the bladder during Urodynamics on the rate of post procedure urinary tract infections in patients with spinal cord injuries |
|
|
| Recruiting | 3 | 200 | | | North Sydney Local Health District, Royal North Shore Hospital , Ramsay Health | Urinary Tract Infection | | | | |
2007-000919-29: Study on reversible effect on muscle of the botulinica toxin on the prevention of the post-traumatic rigidity of elbow |
|
|
| Ongoing | 3 | 60 | Europe | Powder for solution for injection, BOTOX | ISTITUTI ORTOPEDICI RIZZOLI | omero mono-Inter-sovra-sovraintercondiloidee fractures of distant them, fractures of capitello radial and fractures of olecrano with or without luxation | | | | |
2010-018904-94: EFFICACY AND SAFETY OF INTRAMUSCULAR NERIDRONATE IN OSTEOPOROTIC PATIENTS AFFECTED BY PARKINSON'S DISEASE EFFICACIA E SICUREZZA DEL NERIDRONATO INTRAMUSCOLARE NEL TRATTAMENTO DELL OSTEOPOROSI IN PAZIENTI PARKINSONIANI |
|
|
| Ongoing | 3 | 60 | Europe | Solution for injection, NERIXIA*IM EV 1F 25MG | FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE | Osteoporosis in patients affected by Parkinson's disaease at the stages 1-2-3-4 following Hoehn and Yahr criteria Osteoporosi in pazienti con m. di Parkinson stadi 1-2-3-4 sec Hoehn e Yahr, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2011-001888-51: Porovnani ucinnosti a bezpecnosti pripravku MD-Lumbar, MD-Neural a MD-Muscle v porovnani s trimecainem (Mesocainem) u pacientu s akutni bolesti bederni patere. |
|
|
| Ongoing | 3 | 100 | Europe | MD-Lumbar, MD-Muscle, MD-Neural, Mesocain 1% inj. sol., 0000502, Solution for injection, Mesocain 1% inj. sol. | Inpharm, Inpharm | low back pain, low back pain, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2011-003678-97: Exploration of TNF-alpha Blockade with golimumab in the Induction of Clinical Remission in Patients with Early Peripheral Spondyloarthritis (SpA) according to ASAS-criteria Exploratie van TNF alfa blokkade met golimumab met als doel het induceren van klinische remissie bij patiënten met perifere spondyloarthropathie met vroegtijdige aantasting die voldoen aan de huidige ASAS criteria (CRESPA). |
|
|
| Ongoing | 3 | 60 | Europe | golimumab, LEDERTREXATE, Solution for injection in pre-filled syringe, Tablet, Simponi, LEDERTREXATE | Ghent University Hospital, Gheny University Hospital, Janssen Biologics BV | Early stage peripheral Spondyloarthritis (SpA) Vroegtijdige Perifere sponyloarthropathie, Early stage Peripheral Spondyloarthritis Perifere spondyloarthropathie met vroegtijdige aantasting, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2011-004300-38: Does hydroxychloroquine provide effective pain relief for people with hand osteoarthritis? |
|
|
| Ongoing | 3 | 252 | Europe | Hydroxychloroquine, n/a, Tablet, Plaquenil | University of Leeds, Arthritis Research UK | Hand osteoarthritis, Pain in joints of the hand, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2011-004393-28: Effectives of leech therapy Wirksamkeit der Blutegeltherapie |
|
|
| Ongoing | 3 | 44 | Europe | Medirud®Biebertal, Living tissue equivalent, Medirud®Biebertal | Charité - Universitätsmedizin Berlin, Karl und Veronika Carstens Stiftung Essen, Biebertaler Blutegelzucht | chronic low back pain-diagnosis assured by specialist (orthopedy, neurology, pain therapy) as chronic low back pain for at least 3 month caused by nonspecific lumbar syndrome- averaged pain intensity during the last 3 month of at least 40mm measured by VAS (visual analog scale) during pain periodson 4 out of 7 days a week Chronische untere Rückenschmerzen-vorbestehende und fachärztlich (Orthopädie, Neurologie, Schmerztherapie) gesicherte Diagnose eines chronischen unspezifischen LWS-Syndroms seit mindestens 3 Monaten-durchschnittliche initiale Schmerzintensität in Schmerzphasen mit Stärke >40 mm auf der VAS von 0 bis 100 mm und Schmerzen an mindestens 4 von 7 Wochentagen in den letzten 3 Monaten als Ausgangswert, chronic low back pain, since at least 3 months Chronischer unterer Rückenschmerz, welcher seit mindestens 3 Monaten besteht., Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2011-000745-21: An international, multicenter, efficacy and safety trial of intravenous zoledronic acid in infants less than one year of age, with severe osteogenesis imperfecta Une étude clinique multicentrique sur d'efficacité et la sécurité de l'acide zoledronique intraveineux chez les nourrissons de moins d'un an atteints d'une ostéogénèse imparfaite sévère. |
|
|
| Ongoing | 3 | 15 | Europe | zoledronic acid, Solution for infusion, ACLASTA | Schriners Hospitals for Children, Shriners Hospital for Children McGill Montreal, Novartis Pharma Canana Inc. | Children suffering from severe Osteogenesis Imperfecta, Children suffering from severe Osteogenesis Imperfecta, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2013-000337-13: Prediction of response to Certolizumab Pegol treatment with MRI of the brain. A multi-center, randomized double-blind controlled study Prediction of response to Certolizumab-Pegol in Rheumatoid Arthritis (PreCePRA) Vorhersage des Ansprechens von Certolizumab Pegol mittels Bildgebung des Gehirns. Eine multicenter, randomisierte doppel-blind Studie. Vorhersage des Ansprechens von Certolizumab-Pegol in der Rheumatoiden Arthritis (PreCePra) |
|
|
| Ongoing | 3 | 156 | Europe | Cimzia, Suspension for injection in pre-filled syringe, Cimzia | Universitätsklinikum Erlangen, UCB Pharma SA | Patients with active Rheumatoid Artrhitis (DAS28 > 3.2) despite DMARD therapy Patienten mit einer aktiver Rheumatoiden Arthritis (DAS28 > 3.2) trotz Therapie mit DMARD, s, RA patients DMARD -IR RA Patienten DMARD-Versager, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2011-003594-28: A comparative observational clinical study on efficacy ofBioSeed®-C and chondrotissue® treatment of cartilage defects in the knee joint. Eine offene vergleichende Studie zur Wirksamkeit von BioSeed®-C und chondrotissue® bei der Behandlung von Knorpeldefekten im Kniegelenk. |
|
|
| Ongoing | 3 | 80 | Europe | BioSeed®-C, Living tissue equivalent, BioSeed®-C | BioTissue Technologies GmbH, BioTissue Technologies GmbH | focal femoral cartilage defects in the knee joint umschriebene femorale Knorpeldefekte im Kniegelenk, clearly differentiated cartilage defect in the knee joint klar abgegrenzter Knorpelschaden im Kniegelenk, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2013-004313-41: Effect of pre-operative pain treatment on postoperative outcome after total hip or knee replacement surgery Effecten van pre-operatieve pijnbehandeling op postoperatieve uitkomsten na totale heup- of knievervanging |
|
|
| Ongoing | 3 | 118 | Europe | Gastro-resistant capsule, hard, Cymbalta | UMCG, Stichting ARGON (reumafonds "Dutch Arthritis Foundation") | Osteoarthritis (knee or hip) Artrose (knie of heup), degenerative joint disease (knee or hip) gewrichtsslijtage (knie of heup), Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2014-000555-93: Abatacept reversing subclinical Inflammation as measured by MRI in ACPA positive Arthralgia |
|
|
| Ongoing | 3 | 98 | Europe | Abatacept, Solution for infusion in pre-filled syringe, Orencia | University Hospital Erlangen, Universitätsklinikum Erlangen, Brisol Myers Squibb | Patients with ACPA (anti citrullinated peptide antibodies) positive arthralgia and OMERACT RAMRIS synovitis (synovialitis or tenosynovitis) or osteitis but without clinical arthritis, defined by joint swelling, Pre clinical phase of RA with joint pain and detection of characteristic antibodies and inflammatory signs detected by MRI (magnetic resonance imaging) but without joint swelling, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2014-001156-28: A randomized, double-blind, placebo controlled study to assess the safety and the efficacy of Neridronate ampoules 25 mg, after repeated intramuscular administrations, in patients with Complex Regional Pain Syndrome type I (CRPS-I) Studio randomizzato, in doppio cieco, controllato verso placebo, volto a valutare la sicurezza e l’efficacia di Neridronato 25 mg fiale, dopo ripetute somministrazioni intramuscolari, in pazienti con sindrome da dolore regionale complesso di tipo I (CRPS-I) |
|
|
| Ongoing | 3 | 90 | Europe | NERIXIA Soluzione iniettabile 25 mg, Solution for injection, NERIXIA Soluzione iniettabile 25 mg | Abiogen Pharma SpA, Abiogen Pharma SpA | Complex Regional Pain Syndrome type I (CRPS-I) Algodistrofia, Complex Regional Pain Syndrome type I (CRPS-I) Algodistrofia, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2014-003529-16: Stratification of biologic Therapies for Rheumatoid Arthritis by Pathobiology |
|
|
| Ongoing | 3 | 219 | Europe | MabThera, RoActmera, Enbrel, Concentrate for solution for infusion, Solution for injection, Solution for injection in pre-filled pen, MabThera, RoActmera, Enbrel | Joint Research & Development Office (QMUL), Medical Research Council, Arthritis Research UK | Rheumatoid Arthritis, Rheumatoid Arthritis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
| Ongoing | 3 | 5000 | Europe | Odanacatib, MK-0822, Tablet | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | osteoporosis, endocrinology, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
NCT01923532: A Follow-up Study of CARTISTEM® Versus Microfracture |
|
|
| Recruiting | 3 | 102 | RoW | Cartistem®, Microfracture | Dong-A Pharmaceutical Co., Ltd. | Cartistem®, Microfracture, Knee Articular Cartilage Injury, Cartilage Defect | 05/15 | | | |
2015-000636-15: A randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica. |
|
|
| Ongoing | 3 | 332 | Europe | Adalimumab (Humira), EMEA/H/C/000481, Solution for injection in pre-filled syringe, Humira (Adalimumab) | Bangor University | Sciatica is a symptom defined as unilateral, well-localised leg pain, with a sharp, shooting or burning quality, that approximates to the dermatomal distribution of the sciatic nerve down the posterior lateral aspect of the leg, and normally radiates to the foot or ankle. It is often associated with numbness or paraesthesia in the same distribution, Sciatica is pain caused by irritation or compression of the sciatic nerve root, the nerve runs from the back of your pelvis, through your buttocks, down both legs, ending at your feet, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2006-004001-26: A Randomised Controlled Trial of Fascia Iliaca Compartment Block vs. Morphine For Pain in Fractured Neck of Femur in the Emergency Department: A Pilot Study |
|
|
| Ongoing | 3 | 44 | Europe | Bupivacaine, Morphine Sulphate, Marcain, Marcain | Nottingham University Hospitals NHS Trust | Suspected isolated hip fracture - Clinical suspicion of hip fracture is defined as the presence of painful, unilateral shortening and external rotation of the lower limb preventing weight-bearing. | | | | |
2007-000262-20: A phase III, 7 days randomised, double-blind, placebo-controlled, parallel group study to assess efficacy of DPZ for reducing the symptoms of post-operative delirium after an elective hip or knee replacement in patients over 65 years old. |
|
|
| Ongoing | 3 | 300 | Europe | Aricept, Aricept | Stanmore Clinical Research Facility Ltd | Post-operative delirium. | | | | |
2008-004578-42: An Imaging Sub-Study of the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium |
|
|
| | 3 | 400 | Europe | MK-0822; Chemical name N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4\'-(methylsulfo, cholecalciferol (Vitamin D3), MK-0822 | Merck & Co. Inc., Merck & Co., Inc. | Postmenopausal Osteoporosis | | | | |
2008-005874-11: A Substudy to Explore Biomarkers of Physical Function in the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated with Vitamin D and Calcium |
|
|
| Ongoing | 3 | 55 | Europe | | Laboratoires Merck Sharp & Dhome-Chibret | This is an exploratory sub-study of Protocol 018 (Eudract N°2007-002693-66) to identify biomarkers of physical function. This biomarker sub-study will use an ongoing clinical study (Protocol 018) for osteoporosis as a starting point for identification of molecular biomarkers in circulating blood for patient identification and sarcopenia progression. Patients recruited in Protocol 018 are women 65 years of age or older with osteoporosis and either 0 or 1 prior vertebral fracture. | | | | |
2009-011920-69: A Quantitative Computed Tomography (QCT) Sub-Study of the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium |
|
|
| Ongoing | 3 | 20 | Europe | | Merck & Co., Inc. | postmenopausal osteoporosis | | | | |
2015-001669-16: Duloxetine for chronic osteoarthritis pain; an important alternative? Duloxetine voor chronische pijn bij artrose; is het een belangrijk alternatief? |
|
|
| Ongoing | 3 | 224 | Europe | Capsule, hard, Duloxetine | Erasmus MC, ZonMW | osteoarthritis artrose, osteoarthritis artrose, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2015-004738-90: Efficacy, safety and general effect of intra-articular and intraosseous infiltrations of Platelet Rich Plasma in patients with knee osteoarthritis: Randomized Clinical Trial Eficacia, seguridad y efecto a nivel general de las infiltraciones intraarticulares e intraóseas de Plasma Rico en Plaquetas en pacientes con artrosis de rodilla: Ensayo ClÃnico Aleatorizado |
|
|
| Ongoing | 3 | 60 | Europe | PRP (Obtenido por PRGF-Endoret), Solution for injection | Arthroscopic Surgery Unit, Arthroscopic Surgery Unit | Knee osteoarthritis Artrosis de rodilla, Knee osteoarthritis Artrosis de rodilla, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
ChiCTR-IPR-15007081: Randomized, Sham-Controlled Trial of Jintiange for the prevention of the Management of Aromatase Inhibitor–Associated Joint Symptoms inWomenWith Breast Cancer |
|
|
| Completed | 3 | 70 | | Jintiange and Caltrate D ;Caltrate D | Guanganmen Hospital, China Academy of Chinese Medical Sciences; Guanganmen Hospital, China Academy of Chinese Medical Sciences, self-funding | AI-Associatied Musculoskeletal Symptoms | | | | |
2011-005228-17: Can treatment with vitamin D lower the incidence of osteoporosis (bone disease increasing the risk of fracture)? Kan behandling med D-vitamin minska förekomsten av benskörhet vid anorexi? |
|
|
| Ongoing | 3 | 200 | Europe | D-vitamin olja, Calcichew-D3, A11CC, VItamin D, Calcichew-D3, VItamin D, Calcichew-D3 | Kalmar County Council | Osteoporosis in anorexia nervosa Osteoporos vid anorexi | | | | |
2016-003087-40: Interest of intraveinous iron and tranexamic acid to reduce transfusion in hip fracture patients - HIFIT Study Intérêt du fer intraveineux et de l'acide tranexamique dans la réduction transfusionnelle chez les patients souffrant d'une fracture du col du fémur - Etude HIFIT |
|
|
| Not yet recruiting | 3 | 780 | Europe | MONOFER, EXACYL 500mg-5mL, Solution for injection, MONOFER 1000mg-10mL, EXACYL 500mg-5mL | UHangers, UHAngers | Hip fracture Fracture du col du fémur, Hip Fracture Fracture du col du fémur, Body processes [G] - Bones and nerves physological processes [G11] | | | | |
2017-001728-23: Efficacy of golimumab in early axial spondyloarthritis (axSpA) in relation to gut inflammation, an early remission induction study (GO GUT). |
|
|
| Ongoing | 3 | 147 | Europe | Solution for injection in pre-filled pen, Simponi | Ghent University, Merck Sharp & Dohme, Vlaams Instituut voor Biotechnologie | early axial spondyloarthritis (axSpA) in relation to gut inflammation, early axial spondyloarthritis (axSpA) in relation to gut inflammation, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2016-000252-99: Randomly ordered clinical trial to evaluate the efficacy and safety of an etofenamate 5% cutaneous patch vs. placebo in the treatment of acute uncomplicated one sided ankle sprain. Zufallsverteilte klinische Studie zur Bewertung der Wirksamkeit und Sicherheit der Anwendung eines Etofenamat 5%-Pflasters gegenüber Placebo bei Patienten mit akuter, unkomplizierter, einseitiger Sprunggelenkverstauchung. |
|
|
| Not yet recruiting | 3 | 152 | Europe | Etofenamate 5% cutaneous patch, Medicated plaster | Drossapharm AG, Drossapharm AG | Ankle sprain, grade I or II Akute Sprunggelenksverstauchung, Grad I oder II, Ankle sprain, grade I or II Akute Sprunggelenksverstauchung, Grad I oder II, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2016-003154-32: Trial of locally injected pain medication for post-operative recovery after knee replacement surgery |
|
|
| Not yet recruiting | 3 | 500 | Europe | EXPAREL, bupivacaine hydrochloride, Suspension for injection, EXPAREL, bupivacaine hydrochloride | University of Leeds, National Institute of Health Research (NIHR) Research for Patient Benefit (RfPB), Pacira Pharmaceuticals Inc. | Local anaesthetic for patients undergoing knee replacement surgery for arthritis, Local anaesthetic for patients undergoing knee replacement surgery for arthritis, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] | | | | |
| Not yet recruiting | 3 | 150 | Europe | Xeomin, Hydrocortancyl, Powder for injection, Suspension for injection, Xeomin, Hydrocortancyl | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), DGOS | Patients suffering from unilateral lateral epicondylitis, persistent for more than 3 months or recurrent and not having responded to at least one reference treatment Patients ayant une épicondylite latérale unilatérale, persistante depuis plus de 3 mois ou récidivante et n'ayant pas répondu à au moins un traitement de référence, NA NA, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2016-004342-28: A study to compare the absorption into the body of the drug sodium oxybate in FT218 in comparison to the currently marketed product Xyrem®. |
|
|
| Ongoing | 3 | 24 | Europe | Sodium Oxybate for Extended Release Oral Suspension, Xyrem 500mg/ml oral solution, FT218, Powder for oral suspension, Oral solution, Xyrem® 500mg/ml Oral Solution | Flamel Ireland Ltd trading under the business name Avadel Ireland, Flamel Ireland Limited trading under the business name Avadel Ireland | A trial on healthy volunteer fore the development of a treatment for cataplexy and excessive daytime sleepiness in narcolepsy., Cataplexy is an abrupt temporary loss of voluntary muscular function and tone. Narcolepsy which is an neurological disorder that affects the control of sleep and wakefulness., Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2017-001223-49: A clinical trial to evaluate the safety and efficacy of Ataluren versus placebo in people who have specific genetic disease Duchenne Muscular Dystrophy |
|
|
| Ongoing | 3 | 250 | Europe | ataluren, PTC124, Granules in sachet, Translarna 125 mg granules for oral suspension, Translarna 250 mg granules for oral suspension, Translarna 1000 mg granules for oral suspension | PTC Therapeutics, Inc., PTC Therapeutics, Inc. | Nonsense Mutation Duchenne Muscular Dystrophy, Duchenne Muscular Dystrophy, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2017-004530-29: This Phase III study will compare the efficacy and tolerability of a combination IM product of Thiocolchicoside and Diclofenac vs. Diclofenac (Voltaren®) IM in patients with acute low back pain Αυτή η Φάσης ΙΙΙ μελÎτη θα συγκÏίνει την αποτελεσματικότητα και ανεκτικότητα ενός Ï€Ïοϊόντος ÏƒÏ…Î½Î´Ï…Î±ÏƒÎ¼Î¿Ï ÎµÎ½Î´Î¿Î¼Ï…ÏŠÎºÎ¬ χοÏηγοÏμενου Θειοκολχικοσίδη και Δικλοφενάκης Îναντι της ενδομυικά χοÏηγουμÎνης Δικλοφενάκης (Voltaren®) σε ασθενείς με οξεία οσφυαλγία |
|
|
| Ongoing | 3 | 134 | Europe | Diclofenac/Thiocolchicoside, Solution for injection, VOLTAREN | WinMedica SA, WinMedica SA | Acute low back pain (LBP) Οξεία Οσφυαλγία, Acute low back pain is a low back pain present for up to six weeks. It may be experienced as aching, burning, stabbing, sharp or dull. The intensity may range from mild to severe H οξεία οσφυαλγία είναι Îνας χαμηλός πόνος στην πλάτη που διαÏκεί Îως και Îξι εβδομάδες. ΜποÏεί να βιωθεί ως πόνος, αίσθημα καυσίματος, μαχαίÏωμα. Η Îνταση μποÏεί να κυμαίνεται από ήπια Îως σοβαÏή, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2017-004079-30: Stratification of biologic Therapies for Rheumatoid Arthritis by Pathobiology |
|
|
| Ongoing | 3 | 219 | Europe | MabThera, RoActmera, Enbrel, Concentrate for solution for infusion, Solution for injection, Solution for injection in pre-filled pen, MabThera, RoActmera, Enbrel | Joint Research & Development Office (QMUL), AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA, Medical Research Council, Arthritis Research UK, Queen Mary University of London (QMUL) | Rheumatoid Arthritis, Rheumatoid Arthritis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2018-002650-67: Efficacy of plasma injections, and extracorporeal shock wave therapy, in thetreatment of work –related lateral epicondylitis Eficacia de las infiltraciones con plasma y de la terapia con ondas de choque, en eltratamiento de la epicondilitis de origen laboral. |
|
|
| Ongoing | 3 | 66 | Europe | platelet rich plasma, platelet rich plasma, Solution for injection in pre-filled syringe | Ibermutuamur (Mutua Colaboradora con la Seguridad Social nº 274), Ibermutuamur (Mutua Colaboradora con la Seguridad Social | The epicondylitis is an overuse injury, in most cases, is a self-limited course andresponds well to conservative treatment. Its etiology is degenerative and is relatedto a repetitive overuse and underlying tendinopathy. La epicondilitis es una lesión provocada por movimientos repetitivos que en lamayor parte de los casos tiene un curso autolimitado y responde bien al tratamiento conservador. Su etiología es degenerativa y se relaciona con un sobreuso repetitivo y tendinopatía subyacente., The overuse of the muscles attached to the lateral bone of the elbow (epicondyle), as occurs in some jobs and also tennis players, causing its inflammation, known as epicondylitis. El uso excesivo de los músculos que se unen al hueso lateral del codo (epicóndilo), como ocurre en algunos trabajos y también en los tenistas, ocasionan su inflamación, conocida como epicondilitis., Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2017-004601-40: Methoxyflurane efficacy and safety in hostile environment Efficacia e sicurezza del metossiflurano vaporizzato somministrato a pazienti soccorsi mediante elisoccorso in ambienti non raggiungibili da altri mezzi di soccorso |
|
|
| Not yet recruiting | 3 | 200 | Europe | metossiflurano vaporizzato, [metossiflurano vaporizzato], Nebuliser solution, Penthrox® | MUNDIPHARMA RESEARCH LIMITED, Mundipharma Pharmaceutical s.r.l. | moderate to severe pain secondary to minor trauma dolore da moderato a severo secondario a trauma minore, traumatic pain dolore in seguito a trauma, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
NCT03555838: Combined Robotic Training and tDCS in Chronic SCI |
|
|
| Active, not recruiting | 3 | 13 | US | transcranial direct current stimulation, sham transcranial direct current stimulation | Burke Medical Research Institute, New York State Spinal Cord Injury Research Board (SCIRB) | Spinal Cord Injuries, Tetraplegia | 01/19 | 12/23 | | |
2018-003565-33: . Intérêt de la corticothérapie préopératoire sur la cicatrisation après ostéosynthèse des fractures du membre inférieur |
|
|
| Not yet recruiting | 3 | 120 | Europe | Concentrate for solution for injection, Solution for injection, METHYLPREDNISOLONE, CHLORURE DE SODIUM | CHU de Clermont-Ferrand | FRACTURE DE LA JAMBE, FRACTURE DE LA JAMBE, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04] | | | | |
2014-003484-38: Evaluation de l'efficacité du Tocilizumab dans l'arthrose digitale invalidante et réfractaire aux traitements usuels |
|
|
| Not yet recruiting | 3 | 90 | Europe | RoActemra, EMEA/H/C/000955, Concentrate for solution for injection, Roche Registration Limited | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | Patients atteints d'arthrose digitale (IPD et IPP) selon les critères de l'ACR symptomatique (douleur au moins 1 jour sur 2 dans le dernier mois) évoluant depuis plus de 3 mois, patients souffrant d'une arthrose digitale invalidante et réfractaire aux traitements usuels, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2018-003505-26: Clinical trial to evaluate the efficacy, safety and tolerability of Neridronate versus Placebo in patients with transient osteoporosis of the hip. Studio clinico per valutare l'efficacia, la sicurezza e la tollerabilità del Neridronato verso il Placebo in pazienti con osteoporosi transitoria dell'anca. |
|
|
| Ongoing | 3 | 60 | Europe | Nerixia, [035268022], Concentrate for solution for infusion, NERIXIA - 100 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE 2 FIALE | ABIOGEN PHARMA S.P.A. | Transient osteoporosis of the hip. Osteoporosi transitoria dell'anca., Transient osteoporosis of the hip. Osteoporosi transitoria dell'anca., Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2019-000895-40: Beta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia Gravis |
|
|
| Not yet recruiting | 3 | 30 | Europe | Capsule, Salbutamol WZF 4 mg | Aarhus University Hospital, Aarhus University Hospital | Myasthenia Gravis, myasthenia gravis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2018-002929-36: EFFICACY OF CORTICOIDS VS BOTULINIC TOXIN IN THE TREATMENT OF PLANTAR FASCITIS EFICACIA DE CORTICOIDES VS TOXINA BOTULÍNICA EN EL TRATAMIENTO DE LA FASCITIS PLANTAR |
|
|
| Not yet recruiting | 3 | 70 | Europe | IncobotulinumtoxinA, Triamcinolona acetónido, IncobotulinumtoxinA, Triamcinolona acetónido, Powder for solution for injection, Suspension for injection, Xeomin®, TRIGON DEPOT® | Dra. Virginia Raquel Céspedes Nava, NA | Plantar fasciitis Fascitis plantar, Plantar fasciitis Fascitis plantar, Body processes [G] - Physical Phenomena [G01] | | | | |
2017-001249-28: Clinical trial to determine whether the use of blood growth factors in patients with epicondylitis (tennis elbow) at workplace resistant to conservative treatment is better than infiltration with corticoids or the enlargement of the conservative treatment. Ensayo clínico para determinar si el tratamiento con factores sanguíneos de crecimiento en pacientes con epicondilitis (codo del tenista) adquirida en ambiente laboral es mejor que la infiltración con corticoides o el alargamiento del tratamiento conservador. |
|
|
| Not yet recruiting | 3 | 456 | Europe | PRP, , Injection, Celestone Cronodose, Mepivacaine | Mutua Universal MUGENAT, Mutua Universal MUGENAT | Epicondylitis Epicondilitis, Tennis elbow Codo del tenista, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2017-001296-23: The efficacy of botulin toxin A injection in the pelvic floor muscles in the treatment of chronic pelvic pain. |
|
|
| Not yet recruiting | 3 | 92 | Europe | Botox, Powder and solution for solution for injection, Botox | Radboudumc, Radboudumc | Patients with >6 months or recurrent episodes of abdomino-perineo-pelvic pain, hypersensitivity or discomfort often associated with elimination changes, and sexual dysfunction in the absence of organic etiology (definition of the International Continence Society (ICS)) with (primary of secondary) pelvic floor muscle hypertonicity refractory to first line pelvic floor physiotherapy, willing to participate in this trial., chronic pelvic pain without anatomic cause and with pelvic floor muscles hypertonicity, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2018-003709-25: To compare the response of treatment with platelet rich plasma or saline solution injections in patients with shoulder pain. Comparar la respuesta al al tratamiento mediante plasma rico en plaquetas o inyección con suero salino en pacientes con dolor de hombro. |
|
|
| Not yet recruiting | 3 | 60 | Europe | Platelet Rich Plasma, PRP, Blood fraction modifier, Platelet Rich Plasma | Hospital Son Llatzer, Hospital Son Llatzer | Shoulder pain due to rotator cuff tendinopathy or partial tears of the supraspinatus tendon Dolor de hombro secundario a tendinopatía o rotura parcial del tendón del supraespinoso, Shoulder pain due to tendon injury Dolor de hombro debido a lesión de los tendones del hombro, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2019-001678-26: Erectus nerve block for lumbar spine surgery : a prospective randomized study |
|
|
| Not yet recruiting | 3 | 50 | Europe | NAROPEINE 5 mg/ml, solution injectable, Solution for injection, NAROPEINE 5mg | CHU de NIMES, CHU de NIMES | Chirurgie d'arthrodèse, Chirurgie d'arthrodèse, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2019-000538-21: PAINFUL SYNDROME OF THE MAJOR TROCANTER: Randomized clinical trial with masked evaluation of parallel groups to evaluate the efficacy and safety of the sub-fascial infiltration of PRP compared with wet tenotomy. SINDROME DOLOROSO DEL TROCANTER MAYOR: Ensayo clínico, aleatorizado, con evaluación enmascarada de grupos paralelos para evaluar la eficacia y seguridad de la Infiltración sub-fascial de PRP en comparación con la tenotomía húmeda. |
|
|
| Not yet recruiting | 3 | 80 | Europe | Platelets Rich Plasma, Lidocaine, Calcium chloride, PRP, Lidocaine, Calcium chloride, Solution for injection, Lidocaine, Calcium chloride | ISABEL ANDIA ORTIZ, Instituto de Investigación Sanitaria BioCruces Bizkaia | Painful syndrome of the greater trochanter (chronic GTPS) Síndrome doloroso del trocánter mayor (GTPS crónico), Painful syndrome of the greater trochanter Síndrome doloroso del trocánter mayor, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2018-000552-18: Denosumab in the prevention of immobilization-induced bone loss in Intensive Care Unit patients Denosumab in der Vorbeugung des immobilisations-bedignten Knochenabbaus intensivpflichtiger Patienten |
|
|
| Ongoing | 3 | 66 | Europe | Denosumab, Solution for injection, Prolia | Medical University of Vienna, Medical University of Vienna | Immobilization because of aneurysmal subarachnoidal haemorrhage (aSAH) with moderate-severe neurological deficits (e.g. hemiparesis) and reduced state of consciousness – equivalent to Hunt&Hess 4-5 – at the time of admission to ICU Immobilisation aufgrund einer aneurysmatischen Subarachnoidalblutung mit moderaten bis schweren neurologischen Defiziten (z.B.Hemiparese) aud reduziertem Bewusstsein – äquivalent Hunt&Hess 4-5 – zum Zeitpunkt der Aufnahme auf die Intensivstation, Immobilization because of reduced consciousness and neurological deficits because of an intracranial bleeding Immobilisation aufgrund von Bewusstseineintrübung und neurologischen Ausfällen bedingt durch eine Hirnblutung, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
| Not yet recruiting | 3 | 136 | Europe | Terrosa, FORSTEO, Suspension for injection in cartridge, Solution for injection in pre-filled pen, Terrosa, FORSTEO | Norfolk and Norwich University Hospitals NHS Foundation Trust | Healthy individuals with stress fractures., Healthy individuals with stress fractures., Body processes [G] - Bones and nerves physological processes [G11] | | | | |
NCT01656902 / 2011-005798-22: Phase III Study to Evaluate Safety and Effectiveness of NOVOCART 3D Plus vs. Microfracture in Knee Cartilage Defects |
|
|
| Completed | 3 | 263 | Europe, RoW | NOVOCART® 3D plus, Matrix-associated autologous chondrocyte implantation, Microfracture, Microfracture according to Steadman | Tetec AG | Traumatic Articular Cartilage Defects in the Knee Joint | 03/20 | 02/23 | | |
2019-002446-21: Phase III, multicentre, randomized, open clinical trial comparing treatment with allogenic mesenchymal cells against autologous mesenchymal cells and against active control with hyaluronic acid in patients with knee osteoarthritis. Ensayo clínico fase III, multicéntrico, aleatorizado, abierto, de comparación del tratamiento con células mesenquimales alogénicas frente a células mesenquimales autólogas y frente a control activo con ácido hialurónico en pacientes con artrosis de rodilla. |
|
|
| Not yet recruiting | 3 | 120 | Europe | Durolane, Autologous mesenquimal cells, Allogenic mesenchymal stem cells, Injection | IBSAL (Instituto de Investigación Biomédica de Salamanca), Instituto de Salud Carlos III | Knee osteoarthritis Osteoartritis de rodilla, Knee osteoarthritis Osteoartritis de rodilla, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2018-003724-36: Efficacy of treatment with DENOsumab of an acute CHARCOT foot in patients with diabetes. |
|
|
| Not yet recruiting | 3 | 38 | Europe | Solution for injection in pre-filled syringe, Prolia | Ole Lander Svendsen, Amgen Limited, Region Hovedstaden, GCP enhederne, Danske Regioner | acute Charcot foot (Charcot arthropathy; ICD-10: DM14.6) in patients with diabetes, Acute Charcot foot is a rare complication to diabetes, which is presenting as a red, swollen foot with increased skin temperature, that is followed by fractures of bones deformity of the foot., Diseases [C] - Hormonal diseases [C19] | | | | |
2019-000660-25: Evaluating Usability of Subcutaneous Auto-injector of CT-P17 in Patients with Moderate to Severe Active Rheumatoid Arthritis |
|
|
| Not yet recruiting | 3 | 60 | Europe | CT-P17, CT-P17, Solution for injection in pre-filled injector | CELLTRION, Inc., Celltrion, Inc | Moderate to Severe Active Rheumatoid Arthritis, Rheumatoid Arthritis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2019-004961-42: Strategy study in patients with peripheral spondyloarthritis, in which it is investigated whether induction of remission can be achieved more quickly with early treatment with a TNF-alpha blocker, compared to standard treatment, and in which also factors (blood, joint biopsy) that predict these outcome are investigated. Strategie-studie bij patiënten met perifere spondyloartritis, waarbij nagegaan wordt of inductie van remissie sneller bereikt kan worden met vroegtijdige behandeling met een TNF-alfa blokker, in vergelijking met de standaardbehandeling, en waarbij tevens onderzoek gebeurt naar factoren (bloed, gewrichtsbiopsie) die deze uitkomst zouden kunnen voorspellen. |
|
|
| Not yet recruiting | 3 | 112 | Europe | Capsule, Solution for injection in pre-filled injector, Solution for injection in pre-filled syringe, Ledertrexate, Simponi | Ghent University Hospital, VIB vzw, MSD Belgium | peripheral spondyloarthritis Perifere spondyloartritis, rheumatic inflammatory disease against the joints and tendons outside the vertebral column reumatische ontstekingsziekte tegenover de gewrichten en pezen buiten de wervelzuil, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2019-004246-15: Study to assess efficacy of secukinumab compared to ustekinumab in adult patients with psoriatic arthritis and previous TNFα-inhibitor treatment failure |
|
|
| Not yet recruiting | 3 | 310 | Europe | Secukinumab, Ustekinumab, AIN457, Solution for injection in pre-filled syringe, Cosentyx, Stelara | Novartis Pharma GmbH, Novartis Pharma GmbH | Psoriatic arthritis, Psoriatic arthritis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2016-003078-41: Influence of treatment with Phlogenzym® on recovery after total hip replacement as a model. |
|
|
| Not yet recruiting | 3 | 40 | RoW | Phlogenzym, Coated tablet, Phlogenzym | MUCOS Pharma CZ s.r.o., Mucos Pharma CZ s.r.o. | Total hip replacement, Total hip replacement, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
NCT06351995: Neostigmine and Glycopyrrolate by Iontophoresis |
|
|
| Active, not recruiting | 3 | 6 | US | Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics, Iontophoresis | James J. Peters Veterans Affairs Medical Center | Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel | 10/22 | 01/25 | | |
NCT03905824: The Effectiveness of Adding Allogenic Stem Cells After Traditional Treatment of Osteochondral Lesions of the Talus |
|
|
| Recruiting | 3 | 70 | RoW | Allogenic stromal mesenchymal cells derived from the umbilical cord, Debridement and microfracture | University of Chile | Osteochondral Fracture of Talus | 12/20 | 12/24 | | |
2018-004740-36: A clinical study to evaluate how safe and effective the drug Deflazacort (EMFLAZA®) compared to placebo is in subjects with Limb-Girdle Muscular Dystrophy Type 2I |
|
|
| Not yet recruiting | 3 | 100 | Europe | EMFLAZA® (deflazacort), EMFLAZA® (deflazacort), Tablet, EMFLAZA® (DEFLAZACORT) | PTC Therapeutics, Inc., PTC Therapeutics, Inc. | Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I), A condition that causes weakness and wasting of the muscles in the arms and legs. The limb-girdle is the bony structure surrounding the shoulder and hip joints, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2019-002570-31: Randomized double-blind controlled trial comparing anakinra to prednisone for gout flare in patients with chronic kidney disease or kidney transplantation |
|
|
| Not yet recruiting | 3 | 234 | Europe | kineret, Solution for injection in pre-filled syringe, Tablet, Kineret, Cortancyl | Assitance Publique - Hôpitaux de Paris, French Ministery of Health | Men and women of more than 18 years old with a stage 4 or 5 kidney insufficiency or or a kidney insufficiency and an untreated gout attack Hommes et femmes de plus de 18 ans ayant une insuffisance rénale stades 4/5 ou une transplantation rénale et une crise de goutte non traitée, Men and women of more than 18 years old with a stage 4 or 5 kidney insufficiency or or a kidney insufficiency and an untreated gout attack Hommes et femmes de plus de 18 ans ayant une insuffisance rénale stades 4/5 ou une transplantation rénale et une crise de goutte non traitée, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2020-000107-36: Proof of efficacy, maintenance of efficacy, long-term safety andinvestigation of the potential for dependence and abuse and the effect ofabrupt drug withdrawal of VER-01 in a multicenter study in the treatmentof patients with chronic non-specific low back pain |
|
|
| Not yet recruiting | 3 | 808 | Europe | VER-01, Oral solution | Vertanical GmbH, Vertanical GmbH | For the treatment of patients with chronic non-specific low back pain when drug treatment is indicated and previous optimised treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance., Chronic Low Back Pain, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2019-002351-42: Observational Study of VIB4920 to Evaluate the Duration of Clinical and Pharmacodynamic Efficacy of VIB4920 |
|
|
| Not yet recruiting | 3 | 17 | Europe | | Viela Bio, Inc., Viela Bio Inc. | Rheumatoid Arthritis, Rheumatoid Arthritis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2016-003939-38: Short-term efficacy of a single ultrasound-guided intra-articular injection of botulinum toxin A associated to splinting for base-of-thumb osteoarthritis on pain at 3 months Efficacité à court terme d'une injection intra-articulaire échoguidée de toxine botulinique associée au port d'une orthèse sur mesure dans la rhizarthrose |
|
|
| Not yet recruiting | 3 | 60 | Europe | BOTOX, Powder and solvent for solution for injection, BOTOX | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), AP-HP | Patients referred to our Physical Medicine Rehabilitation Department of a tertiary care center in Paris, France, for the management of Base-of-thumb osteoarthritis (BTOA) Patients de consultation et d'hospitalisation du Service de Rééducation et de Réadaptation de l'Appareil Locomoteur et des Pathologies du Rachis répondant aux critères de classification de l'American College of Rheumatology pour la rhizarthrose, Patients referred for the management of base-of-thumb osteoarthritis Patients répondant aux critères de classification de l'American College of Rheumatology pour la rhizarthrose, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2020-005974-91: Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women with Osteoporosis. |
|
|
| Not yet recruiting | 3 | 440 | Europe | Prolia, CT-P41, Solution for injection in pre-filled syringe, Prolia | Celltrion, Inc, Celltrion, Inc | Osteoporosis is a systemic skeletal disease that is characterized by low bone mass and micro architectural deterioration of bone tissue, with a low bone mineral density (BMD) and consequent increase in bone fragility and susceptibility to fracture. The incidence of fractures varies greatly by country, but on average up to 50% of women > 50 years of age are at risk of fractures. Postmenopausal osteoporosis, resulting from estrogen deficiency, is the most common type of osteoporosis., Osteoporosis is defined as a systemic skeletal disorder characterized by low bone mass and micro architectural deterioration of bone tissue., Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2020-001032-99: The main purpose of this placebo-controlled clinical trial is to compare the efficacy and safety of "Lixim 70 active-substance patch" (Lixim patch), which is applied once daily with the efficacy and safety of the same active ingredient patch applied twice daily in the treatment of acute uncomplicated ankle sprains (distorsions). Hauptzweck dieser Placebo kontrollierten klinischen Prüfung ist der Vergleich der Wirksamkeit und Sicherheit von „Lixim 70 wirkstoffhaltiges Pflaster“(Lixim Pflaster), welches einmal täglich aufgetragen wird mit der Wirksamkeit und Sicherheit des gleichen wirkstoffhaltigen Pflasters, welches zweimal täglich aufgetragen wird bei der Behandlung von akuten unkomplizierten Sprunggelenkverstauchungen (Distorsionen). |
|
|
| Not yet recruiting | 3 | 224 | Europe | Etofenamate, Medicated plaster, Lixim 70 mg wirkstoffhaltiges Pflaster | Drossapharm AG, Drossapharm AG | Acute ankle sprain, Grade I, Acute ankle sprain, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2020-005343-23: Study of the antiresorptive treatment with alendronate versus no treatment after denosumab and aromatase inhibitors discontinuation in low fracture risk osteopenic postmenopausal women with non metastatic hormonal receptor positive breast cancer. Studio del trattamento anti-riassorbimento con alendronato rispetto a nessun trattamento dopo l’interruzione della terapia con denosumab e inibitori dell’aromatasi in donne a basso rischio di frattura osteopeniche in post-menopausa affette da carcinoma mammario non metastatico positivo al recettore ormonale. |
|
|
| Not yet recruiting | 3 | 190 | Europe | Acido Alendronico, [Binosto], Effervescent tablet, BINOSTO - 70 MG COMPRESSE EFFERVESCENTI | IRCCS ISTITUTO ORTOPEDICO GALEAZZI S.P.A, Amgen, Abiogen Pharma S.p.A. | post-menopausal osteoporosis in women with non-metastatic hormonal receptor positive (HR+) breast cancer. osteoporosi post-menopausale in donne affette da carcinoma mammario non metastatico positivo per il recettore ormonale (HR+)., post-menopausal osteoporosis in women with non-metastatic hormonal receptor positive (HR+) breast cancer. osteoporosi post-menopausale in donne affette da carcinoma mammario non metastatico positivo per il recettore ormonale (HR+), Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2020-005081-34: A randomized study to evaluate the efficacy and Safety of Baricitinib to induce Remission and to spare Glucocorticoids in subjects with new-onset Polymyalgia Rheumatica. Eine randomisierte Studie zur Beurteilung der Wirksamkeit und Sicherheit von Baricitinib zur Remissionsinduktion und als Glukokortikoid sparender Wirkstoff in Patienten mit früher Polymyalgia rheumatica |
|
|
| Ongoing | 3 | 18 | Europe | Olumiant, LY3009104, Film-coated tablet, Olumiant | Medical University of Vienna, Medical University of Vienna | Polymyalgia rheumatica (PMR), Polymyalgia rheumatica (PMR), Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2020-000624-20: Core decompression versus core decompression followed by infusion of Iloprost in thetreatment of idiopathic non-traumatic avascular necrosis of the femoral head |
|
|
| Ongoing | 3 | 38 | Europe | Concentrate for solution for infusion, Iloprost ratiopharm | Leipzig University, Deutsche Forschungsgemeinschaft (DFG) | idiopathic non-traumatic avascular necrosis of the femoral head (IN-ANFH), idiopathic non-traumatic avascular necrosis of the femoral head (IN-ANFH), Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
| Ongoing | 3 | 410 | Europe | Prolia, EB1001, Solution for injection in pre-filled syringe, Prolia | Eden Biologics, Inc., Taiwan, Eden Biologics, Inc., Taiwan | Osteoporosis is a disorder of impaired bone strength that results in skeletal fragility and increased fracture risk. It is a common and costly disorder, and is associated with significant morbidity and mortality., Osteoporosis is a disease where bones deteriorate and become less dense, more porous, and brittle. The decrease in bone mass and strength leads to increased fragility and risk of fracture., Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2020-005732-29: Efficacy and Safety Study of Nipocalimab IV Infusions for Adults With Generalized Myasthenia Gravis Estudio de eficacia y seguridad de las infusiones i.v. de nipocalimab para adultos con miastenia grave generalizada |
|
|
| Ongoing | 3 | 105 | Europe | Nipocalimab, JNJ-80202135, Solution for infusion | Janssen-Cilag International N.V., Janssen Research & Development, LLC | Myasthenia gravis (MG). Miastenia grave (MG), Myasthenia gravis, a neuromuscular disease. Miastenia grave, una enfermedad neuromuscular, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2020-004809-31: Study of efficacy and safety of secukinumab 300 mg in patients with giant cell arteritis (GCA). |
|
|
| Not yet recruiting | 3 | 349 | Europe, RoW | Cosentyx, Prednisone, AIN457, Solution for injection in pre-filled syringe, Capsule, hard + tablet, Cosentyx, Prednisone | Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Pharma AG | giant cell arteritis, giant cell arteritis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
NCT05060406: A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture |
|
|
| Recruiting | 3 | 448 | RoW | LY06006, recombinant human monoclonal anti-RANKL antibody injection | Luye Pharma Group Ltd., Shang Dong Boan Biotechnology Co., Ltd (Co-sponsor) | Postmenopausal Osteoporosis | 09/21 | 12/21 | | |
2018-004057-25: Comparison between Ibuprofen by mouth and Ketorolac by mouth to offer relief from trauma pain. Confronto tra Ibuprofene per bocca e Ketorolac per bocca per offrire sollievo dal dolore da trauma. |
|
|
| Not yet recruiting | 3 | 250 | Europe | Ibuprofene, Ketorolac, [034102386], [027253069], Oral suspension, Oral drops, solution | IRCCS MATERNO INFANTILE BURLO GAROFOLO, Fondi della Direzione Scientifica - IRCCS Burlo Garofolo | Pain is present in 78% of overall accesses in pediatric emergency rooms and, in most cases, it is acute and secondary to musculoskeletal trauma. Fifthy percent of patients report moderate to severe pain.It is difficult to assess the pain in children and the data are scarce about the most appropriate pain-killer therapy for pediatric patients. The most commonly used drugs are non-steroidal anti-inflammatory drugs and acetaminophen. Il dolore è presente nel 78% degli accessi complessivi in pronto soccorso pediatrico e, nella maggior parte dei casi, è acuto e secondario ad un trauma muscoloscheletrico; circa la metà dei pazienti riporta un dolore da moderato a grave. Risulta difficile valutare il dolore nel bambino e i dati sono scarsi su quale sia la terapia antidolorifica più adatta per i pazienti pediatrici, i farmaci più comunemente impiegati sono gli antinfiammatori non steroidei FANS e il paracetamolo., Treatment in emergency department of acute musculoskeletal pain secondary to trauma in children Trattamento in pronto soccorso del dolore acuto da trauma muscolo scheletrico nei bambini, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2021-002534-16: Placebo-controlled, pharmacological clinical trial to evaluate the effectiveness, cost-utility and neurobiological effects Naltrexone in patients with fibromyalgia Ensayo clínico controlado con placebo para evaluar la efectividad, coste-utilidad y efectos neurobiológicos de la Naltrexona en pacientes con fibromialgia |
|
|
| Not yet recruiting | 3 | 120 | Europe | Naltrexone, Film-coated tablet | Fundació Sant Joan de Déu, Instituto de Salud Carlos III (ISCIII) | Fibromyalgia Fibromialgia, Fibromyalgia Fibromialgia, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2021-003958-23: EVALUATION OF SPIRONOLACTONE EFFECTIVENESS IN PATIENT WITH RHEUMATOID ARTHRITIS (RA) EVALUATION DE L’EFFICACITE DE LA SPIRONOLACTONE CHEZ DES PATIENTS ATTEINTS DE POLYARTRITE RHUMATOIDE (PR). |
|
|
| Not yet recruiting | 3 | 154 | Europe | Tablet, Spironolactone Mylan 25 mg comprimé pelliculé sécable | Hopitaux Universitaires de Strasbourg, INTERREG RHIN SUPERIEUR | RHEUMATOID ARTHRITIS POLYARTHRITE RHUMATOIDE, RHEUMATOID ARTHRITIS POLYARTHRITE RHUMATOIDE, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2020-002765-34: A Study Comparing MabionCD20 (new Rituximab biosimilar) with MabThera (reference Rituximab from EU) and Rituxan (reference Rituximab from US) in Patients with Rheumatoid Arthritis |
|
|
| Not yet recruiting | 3 | 280 | Europe | MabionCD20, Concentrate for solution for infusion, MabThera, Rituxan | Mabion S.A., Mabion S.A. | Moderate-to-severe rheumatoid arthritis, Rheumatoid Arthritis is a disease which causes joint inflammation and pain. The study is done in patients with rheumatoid arthritis of moderate to severe activity., Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2021-001376-42: A clinical trial comparing muscle cell treatment with placebo in fecal incontinence patients Un ensayo clínico que compara el tratamiento con células musculares y placebo en pacientes con incontinencia fecal |
|
|
| Not yet recruiting | 3 | 290 | Europe, RoW | autologous Skeletal Muscle Derived Cells (aSMDC), ICEF15, Suspension for injection | Innovacell AG, Innovacell AG | Fecal incontinence Incontinencia fecal, Accidental bowel leakage Fugas intestinales accidentales, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
NCT01896011: Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures |
|
|
| Completed | 3 | 34 | Canada | Teriparatide 20 mcg, Brand name Forteo, Placebo | University Health Network, Toronto, The Physicians' Services Incorporated Foundation, Eli Lilly and Company | Non Displaced Atypical Femoral Fractures | 12/21 | 12/22 | | |
NCT04865380: Does Tranexamic Acid Improve Visualization During Arthroscopic Rotator Cuff Repair |
|
|
| Recruiting | 3 | 50 | Canada | Tranexamic Acid 100 MG/ML, Sandoz Tranexamic Acid Injection BP 100mg/mL, DIN 02246365 | University of Saskatchewan | Rotator Cuff Tears, Rotator Cuff Injuries, Subacromial Impingement, Subacromial Impingement Syndrome | 12/21 | 04/22 | | |
ChiCTR2000032882: Phase III clinical trial of recombinant anti-RANKL human monoclonal antibody injection (LY06006) |
|
|
| Recruiting | 3 | 448 | | LY06006 injection 60mg, the control group was given a placebo, both were 1mL, subcutaneously injected, administered every 6 months until the 12th month, a total of 2 times ;Placebo; 1mL, subcutaneous injection, administered every 6 months, up to 12 months, a total of 2 doses | Shanghai Sixth People's Hospital; Shandong Boan Biotechnology Co., Ltd., Shandong Boan Biotechnology Co., Ltd. | Osteoporosis | | | | |
ChiCTR2100046208: Clinical Trial Plan for the Safety and Efficacy Appraisal of HK.SWT-007 Shock Wave Therapy System in the Treatment of Hip Joint Pain Caused by Femoral Head Necrosis |
|
|
| Recruiting | 3 | 120 | | Extracorporeal shock wave therapy(ESWT) ;Celecoxib is taken orally | The Third Medical Center of the PLA General Hospital; The Third Medical Center of the PLA General Hospital, Self-raised | Necrosis of femoral head | | | | |
| Enrolling by invitation | 3 | 160 | US | Saphenous Nerve Block, Ropivacaine injection | Rothman Institute Orthopaedics | Pain, Joint, Pain, Procedural, Meniscectomy | 01/22 | 01/22 | | |
2021-001256-34: study to demonstrate the efficacy and safety of secukinumab up to 224 weeks in subjects with active peripheral spondyloarthritis (pSpA). Klinické skúšanie na zhodnotenie účinnosti a bezpečnosti sekukinumabu do 224 týždňov liečby u pacientov s aktívnou periférnou spondyloartritídou (pSpA) |
|
|
| Ongoing | 3 | 324 | Europe | Solution for injection in pre-filled syringe, Cosentyx | Novartis Pharma AG, Novartis Farmacéutica, S.A., Novartis Pharma AG | Peripheral Spondyloarthritis, Peripheral Spondyloarthritis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2021-001465-20: Clinical trial to assess the efficacy and safety of Montelukast in patients with erosive / inflammatory arthrosis of the hands Ensayo clínico para evaluar la eficacia y seguridad de Montelukast en pacientes con artrosis erosiva/inflamatoria de manos |
|
|
| Not yet recruiting | 3 | 280 | Europe | Montelukast sodium, Capsule, hard | Laboratorios Farmalíder S.A., Laboratorios Farmalíder S.A. | Erosive / inflammatory arthrosis of the hands Artrosis erosiva/inflamatoria de manos, Erosive / inflammatory arthrosis of the hands Artrosis erosiva/inflamatoria de manos, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2021-003914-38: Different antimicrobial durations for the treatment of infections associated with OsteosynthesisMaterial implanted after long bone fractures DIFERENTES DURACIONES DE TRATAMIENTO ANTIMICROBIANO DE INFECCIONES ASOCIADAS AL MATERIAL DE OSTEOSÍNTESIS TRAS FRACTURA DE HUESO LARGO |
|
|
| Not yet recruiting | 3 | 378 | Europe | Ampicillim, amoxicillin/clavulanic, Cefazolin, Cefepime, Ceftazidime, CEFTRIAXONE, cloxacillin, daptomycin, Meropenem, Teicoplanin, Vancomycin, Amoxicillin, Amoxicillin / clavulanic acid, Ciprofloxacin, Levofloxacin, Linezolid, Moxifloxacin, Rifampicin, Powder and solvent for solution for infusion, Powder and solvent for solution for injection, Powder for solution for injection, Powder and solvent for suspension for injection, Powder for solution for injection/infusion, Tablet, , Capsule, Ampicillim, Amoxicillin/Clavulanic, Cefazolin, Cefepime, ceftazidime, CEFTRIAXONE, cloxacillin, daptomycin, Meropenem, Teicoplanin, Vancomycin, Amoxicillin, Amoxicillin / clavulanic acid, Ciprofloxacin, Clindamycin, Sulfametoxazol trimetoprim, Levofloxacin, Linezolid, Moxifloxacin, Rifampicin | Fundación Pública Andaluza para la Gestión de la Investigación, Instituto de Salud Carlos III. Ministerio de Ciencia e | Patients with long bone fractures who have had osteosynthesis material implanted to stabilize and assist fracturehealing and meet the criteria for Infections associated with osteosynthesis material Pacientes con fracturas de huesos largos a quienes se les ha implantado material de osteosíntesis para estabilizar y ayudar a la curación de la fractura y que cumplen con los criterios de Infecciones asociadas con el material de osteosíntesis., Patients with infections due to the implant used to stabilize a long bone fracture Pacientes con infecciones debidas al implante usado para estabilizar una fractura de hueso largo, Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
NCT04764916: Evaluation of Exparel Adductor Canal Field Block for Pain Control After ACL Reconstruction |
|
|
| Recruiting | 3 | 60 | US | Liposomal bupivacaine, Bupivacaine Hydrochloride | Carilion Clinic | Anterior Cruciate Ligament Tear, Pain, Postoperative, Opioid Use | 02/22 | 03/22 | | |
NCT03179631: Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy |
|
|
| Completed | 3 | 360 | Europe, Canada, Japan, US, RoW | Ataluren, PTC124, PLACEBO, Matching Placebo | PTC Therapeutics | Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Disease, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn | 03/22 | 07/23 | | |
2021-002784-21: Botulinum toxin type A as treatment for chronic facial muscle pain. Botulinumtoxin A som behandling mot långvarig käkmuskelsmärta. |
|
|
| Ongoing | 3 | 72 | Europe | Botox, Powder for solution for injection, BOTOX Allergan | Västra Götalandsregionen, Västra Götalandsregionen | Chronic myalgia (>6months) in the facial region., Chronic muscle pain (>6months) in the facial region., Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
